home / stock / oryzf / oryzf news

ORYZF News and Press, Oryzon Genomics S.A. From 04/03/23

Stock Information
Company Name: Oryzon Genomics S.A.
Stock Symbol: ORYZF
Market: OTC
Menu
ORYZF ORYZF Quote ORYZF Short ORYZF News ORYZF Articles ORYZF Message Board
Get ORYZF Alerts

News, Short Squeeze, Breakout and More Instantly...
ORYZF - ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder

Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trial MADRID, Spain and BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging ...
ORYZF - ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-mutant Acute Myeloid Leukemia Patients

In combination with gilteritinib Primary objectives: to assess safety, tolerability and RP2D Secondary objectives: to assess efficacy MADRID, Spain and BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage bio...

ORYZF - ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders

A highly selective HDAC-6 inhibitor Rescues motor-neuronal deficiencies in a Charcot-Marie-Tooth model To start IND enabling studies MADRID, Spain and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biop...

ORYZF - ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology

MADRID, Spain and BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will host a virtual panel di...
ORYZF - ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022

Strong clinical progress in both oncology and CNS Cash, cash equivalents and marketable securities totaled $22.7 million as of December 31, 2022 MADRID, Spain and BOSTON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biophar...

ORYZF - ORYZON to Give Updates on Corporate Progress in February-March

BIO CEO & Investor Conference 2023 IASLC 2023 Targeted Therapies of Lung Cancer Meeting 16th Annual European Life Sciences CEO Forum Cancer Epigenetics Institute Symposium: From Genes to Chromatin to Therapeutics BioCapital Europe 2023 BIO-EUROPE Sp...

ORYZF - ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas

Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECs Part of a broad collaboration with The Cancer Epigenetics Institute (CEI) MADRID, Spain and BOSTON, Jan. 18, 2023 (GLOBE NEWSWIR...
ORYZF - ORYZON to Give Updates on Corporate Progress in January

6th Sachs Annual Neuroscience Innovation Forum 12th Annual LifeSci Advisors Corporate Access Event 41st Annual J.P. Morgan Healthcare Conference Invest Securities Biomed Forum 2023 MADRID, Spain and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Oryzon Genom...

ORYZF - Oryzon Genomics S.A. GAAP EPS of -$0.01

Oryzon Genomics S.A. press release ( OTCPK:ORYZF ): Q3 GAAP EPS of -$0.01. Cash, cash equivalents and marketable securities totaled $27.1 million as of September 30, 2022. For further details see: Oryzon Genomics S.A. GAAP EPS of -$0.01

ORYZF - ORYZON to Give Updates on Corporate Progress in March and April

Virtual Bio-Europe Spring 2022 Kempen Life Sciences Conference Asebio Investor Day MADRID, Spain and CAMBRIDGE, Mass., March 25, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company levera...
Previous 10 Next 10